SCHEMBL12665482

SCHEMBL12665482

CC(C)c1cc2c(cc1F)c(=O)c(C(=O)O)cn2-c1ccc(F)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 6/20 0.49
HSD17B10 Q99714 4/20 0.49
HPGD P15428 3/20 0.49
EPHA2 P29317 1/20 0.48
FLT4 P35916 1/20 0.48
GSK3B P49841 1/20 0.48
RARB P10826 1/20 0.48
TBXAS1 P24557 1/20 0.48
SLC6A3 Q01959 1/20 0.48
POLB P06746 2/20 0.47
HTT P42858 2/20 0.47
XBP1 P17861 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL500692 0.87 LMNA (0.56) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL12665510 0.86 LMNA (0.62) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL10330764 0.85 LMNA (0.55) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL9147090 0.83 EPHA2 (0.53) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL8094560 0.83 EPHA2 (0.53) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL2087613 0.83 LMNA (0.53) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6216178 0.81 LMNA (0.50) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL10412629 0.80 LMNA (0.50) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL10666385 0.80 LMNA (0.81) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL12665479 0.79 EPHA2 (0.60) LMNAKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124597-A1 BORON CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-05-26 US disclosed
US-7265107-B2 Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS INC. (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124597-A1 BORON CONTAINING SMALL MOLECULES BCL6B, BCL6, BLVRB LMNA 4328/4885KMT2A 2682/4885MEN1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.